Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice.
Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline.
Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.
|
|
|
11-50 employees
View all Brii Biosciences employees
|
|
Biotechnology
|
|
110 N Corcoran St, Suite 05-110, One City Center, Durham, North Carolina 27701, US
|
|
2018
|
|
Biotechnology
|
Zhi Hong is the CEO of Brii Biosciences.
The decision makers in Brii Biosciences are Chasity Andrews, Claudia Prilliman, David Margolis, etc. Click to Find Brii Biosciences decision makers emails.
Brii Biosciences focuses on developing innovative therapies for infectious diseases, particularly those with high unmet medical needs. Our pipeline includes treatments for viral infections, such as hepatitis B and COVID-19, as well as other public health challenges. We leverage advanced biotechnology to create solutions that improve patient outcomes and expand treatment options.
Brii Biosciences primarily operates within the biotechnology and pharmaceutical industries. Our work impacts healthcare providers, patients, and public health organizations by addressing critical health challenges. We collaborate with various stakeholders, including research institutions and regulatory bodies, to ensure our therapies meet the needs of diverse populations.
Brii Biosciences identifies areas where patients face significant health challenges and limited treatment options. We conduct extensive research to understand these unmet needs and develop targeted therapies that address them. Our approach includes leveraging cutting-edge technology and scientific expertise to create effective solutions that improve patient care and quality of life.
Our commitment to public health is central to our mission. By focusing on diseases that disproportionately affect vulnerable populations, we aim to reduce health disparities and improve access to effective treatments. We believe that addressing public health challenges not only benefits individual patients but also contributes to the overall health and well-being of communities worldwide.
Brii Biosciences actively collaborates with academic institutions, research organizations, and industry partners to advance our research and development efforts. These collaborations enhance our scientific capabilities, accelerate the development of our therapies, and ensure that we remain at the forefront of biotechnology innovation. We are committed to fostering partnerships that drive meaningful progress in addressing public health challenges.
To stay informed about Brii Biosciences' latest developments, you can visit our website and subscribe to our newsletter. We also share updates through our social media channels, including LinkedIn and Twitter. Additionally, we regularly publish press releases and scientific publications that provide insights into our research progress and product pipeline.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.